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Abstract
Introduction: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease
(CTD). We sought to quantify survival and determine factors predictive of mortality in a cohort of patients with
CTD-associated PAH (CTD-PAH) in the current era of advanced PAH therapy.
Methods: Patients with right heart catheter proven CTD-PAH were recruited from six specialised PAH treatment
centres across Australia and followed prospectively. Using survival methods including Cox proportional hazards
regression, we modelled for all-cause mortality. Independent variables included demographic, clinical and
hemodynamic data.
Results: Among 117 patients (104 (94.9%) with systemic sclerosis), during 2.6 ± 1.8 (mean ± SD) years of follow-up
from PAH diagnosis, there were 32 (27.4%) deaths. One-, two- and three-year survivals were 94%, 89% and 73%,
respectively. In multiple regression analysis, higher mean right atrial pressure (mRAP) at diagnosis (hazard ratio (HR)
= 1.13, 95% CI: 1.04 to 1.24, P = 0.007), lower baseline six-minute walk distance (HR = 0.64, 95% CI: 0.43 to 0.97, P =
0.04), higher baseline World Health Organization functional class (HR = 3.42, 95% CI: 1.25 to 9.36, P = 0.04) and
presence of a pericardial effusion (HR = 3.39, 95% CI: 1.07 to 10.68, P = 0.04) were predictive of mortality. Warfarin
(HR = 0.20, 95% CI: 0.05 to 0.78, P = 0.02) and combination PAH therapy (HR = 0.20, 95% CI: 0.05 to 0.83, P = 0.03)
were protective.
Conclusions: In this cohort of CTD-PAH patients, three-year survival was 73%. Independent therapeutic predictors
of survival included warfarin and combination PAH therapy. Our findings suggest that anticoagulation and
combination PAH therapy may improve survival in CTD-PAH. This observation merits further evaluation in
randomised controlled trials.
Keywords: Connective tissue disease, mortality, prognosis
Introduction
Pulmonary arterial hypertension (PAH) is a major cause
of mortality in connective tissue disease (CTD), particu-
larly in systemic sclerosis (SSc) [1]. Prior to the introduc-
tion of advanced PAH therapies, such as endothelin
receptor antagonists (ERA), prostacyclin analogues and
phosphodiesterase type-5 inhibitors (PDE5), treatment
options for PAH were limited. Current therapies increase
exercise tolerance and improve hemodynamic parameters
[2]. A recent meta-analysis suggests that they also confer
a survival benefit [3]. In one contemporary cohort of
patients with SSc-associated PAH (SSc-PAH), survival
was 81% at one year and 71% at two years, compared to
68% and 47% respectively, in a historical cohort (P =
0.016) [4]. Survival in CTD-associated PAH (CTD-PAH)
is shorter than in idiopathic PAH (IPAH). This remains
the case in the current treatment era, as demonstrated in
a US registry of PAH patients wherein one-year survival
was 86% among patients with CTD-PAH compared to
93% in patients with IPAH (P < 0.0001) [5].
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Currently in Australia, prescription of specific PAH
therapy is limited to government designated PAH treat-
ment centres. All patients with right-heart catheter
(RHC) proven PAH qualify for monotherapy with bosen-
tan, ambrisentan, sildenafil or inhaled iloprost. For
ongoing therapy, patients must demonstrate stability of
both six-minute walk distance (6MWD) and echocardio-
graphic parameters, although they are able to swap to an
alternate agent if these criteria are not met. Combination
PAH therapy is currently available at cost or on compas-
sionate grounds. Sitaxentan was available in Australia
until its worldwide withdrawal in early 2011. Intravenous
prostacyclin analogues were not subsidised in the treat-
ment of CTD-PAH in Australia at the time of this study.
In this study, our objective was to quantify survival
and determine factors predictive of mortality among
Australian patients with CTD-PAH, since the advent of
specific PAH therapies.
Materials and methods
All patients with CTD-PAH diagnosed on RHC [6] from
November 2002 onwards were recruited (at the time of
diagnosis of PAH) from six PAH treatment centres
across Australia and followed prospectively, at three- to
six-month intervals. Date of diagnosis of PAH was
defined as the date of the RHC.
Clinical and hemodynamic variables were recorded dur-
ing follow-up. Data were censored at 31 December 2009
for analysis. Ethics approval was obtained from the human
research ethics committees of St. Vincent’s Hospital
Melbourne, Southern Health, Royal Adelaide Hospital,
Royal Perth Hospital and Central Northern Adelaide
Health Service. Patients in this study provided informed
consent.
Demographic and disease-related variables
All patients had SSc or another underlying CTD, namely
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE) or mixed connective tissue disease (MCTD).
Definitions were based on the American College of
Rheumatology diagnostic criteria for SSc [7], RA [8] and
SLE [9] and the Alarcon-Segovia diagnostic criteria for
MCTD [10]. Patients were defined as having limited or
diffuse SSc according to the classification criteria of
LeRoy et al. [11]. World Health Organization (WHO,
Geneva, Switzerland) functional class (FC) [12] and
6MWD [13] at PAH diagnosis were recorded along with
echocardiographic and RHC parameters. The presence
of pericardial effusion on echocardiography was docu-
mented. We excluded patients with significant intersti-
tial lung disease (ILD) defined based on extensive
disease (> 20% lung involvement) on high-resolution CT
lung (HRCT), or evidence of fibrosis on HRCT together
with forced vital capacity (FVC) < 70% predicted and/or
an FVC to diffusing capacity of carbon monoxide
(DLCO) ratio < 1.6 in whom PAH was deemed second-
ary to lung disease [14]. Other covariates included auto-
antibody profile, anti-phospholipid antibody status
(positive if either anti-cardiolipin or anti-beta2 glycopro-
tein IgG or IgM greater than upper limit of normal for
assay) and the PAH study centre from which the patient
was recruited.
Outcome variable
The outcome variable was all-cause mortality. The date
of death was recorded. Where data were available, the
exact causes of death were also recorded and verified
through chart review. The status (alive or dead) of
patients at the time of censoring was confirmed by
checking with the treating physician and through chart
review. There were no losses to follow-up.
Treatment related variables
Specific PAH therapies, prescribed at physician discre-
tion following RHC-confirmed diagnosis of PAH, were
recorded at each visit. This included ‘combination ther-
apy’, which was defined as treatment with more than
one agent from any of the three classes (ERA, PDE5
inhibitors, prostacyclin analogues) at the same time.
Indications for substitution or addition of a second
agent were documented. We also recorded warfarin
therapy of at least six months’ duration, following PAH
diagnosis. Indications and complications of warfarin
therapy, and target INR were also recorded. In those
who were not anticoagulated, we recorded contraindica-
tions for warfarin therapy as documented by the treating
physician.
Statistical analysis
Patient characteristics at baseline are reported as mean
± standard deviation (SD) for continuous variables and
proportions (percentages) for categorical variables. Dif-
ferences in baseline hemodynamics between SSc patients
and other CTD patients, and patients on monotherapy
vs combination therapy were compared using the Stu-
dent’s t-test. Kaplan-Meier (K-M) curves were used to
estimate survival in all patients and also in SSc patients
compared with those who had other CTDs. Log-rank
and Wilcoxon tests were used to determine univariate
predictors of survival. After testing to ensure propor-
tionality of hazard, Cox proportional hazards regression
analyses were used to determine univariate and multi-
variable predictors of survival. These results were
reported as hazard ratios (HR) with accompanying 95%
confidence intervals (95% CI). Two-tailed P-values ≤
0.05 were considered statistically significant.
All statistical analyses were performed using STATA
11.0 (Statacorp, College Station, TX, USA).
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Results
A total of 117 patients with incident CTD-PAH were
recruited. Patient characteristics and baseline hemody-
namics are summarised in Table 1. During a mean ± SD
follow-up from PAH diagnosis of 2.6 ± 1.8 years, there
were 32 (27.4%) deaths. All but three deaths were pri-
marily due to PAH. In the remaining three deaths due
to malignancy, PAH was a major contributor to death.
Specific PAH therapy
All patients received specific PAH therapy. Seventy
patients (59.8%) received monotherapy, 12 patients
(10.3%) sequential monotherapy and 34 patients (29.0%)
combination therapy (Table 1). The main reasons for
sequential and combination therapy were failure of
initial PAH therapy or drug-related adverse effects sig-
nificant enough to warrant a change in therapy.
Bosentan was the most commonly prescribed medica-
tion, used in 103 patients (88.0%). Sildenafil was the
next most common medication used in 38 patients
(32.5%), followed by sitaxentan in 18 (15.4%) and
inhaled iloprost in 15 (13.4%). The most common com-
bination therapies were bosentan and sildenafil (21
patients), followed by bosentan, sildenafil and inhaled
iloprost (6 patients).
Comparisons of baseline clinical and hemodynamic data
Mean ± SD mPAP at baseline was lower in patients with
SSc than in patients with other CTDs (34.3 ± 11.7 mmHg
vs 49.5 ± 10.3 mmHg, P < 0.001). SSc patients were also
older at PAH diagnosis (62.6 ± 10.3 years vs 54.0 ± 17.1
years, P = 0.01) and had higher baseline 6MWD (334.6 ±
125.2 m vs 235.0 ± 110.3 m, P = 0.02) than patients with
other CTDs.
Among all patients in the study, at baseline, those who
subsequently received combination therapy had higher
mPAP than those who received monotherapy or sequen-
tial monotherapy (40.0 ± 11.6 mmHg vs 34.0 ± 12.4
mmHg, P = 0.02). There were no differences in age at
PAH diagnosis (59.6 ± 11.5 vs 62.5 ± 11.4 years, P = 0.21)
or baseline 6MWD (303.3 ± 114.5 m vs 333.8 ± 131.5 m,
P = 0.27) among the combination vs monotherapy or
sequential monotherapy treatment groups.
Survival and factors predictive of mortality
Twenty-seven of the 32 (84.4%) deaths occurred in
patients with SSc. Overall, one-year survival was 94%,
two-year survival was 89% and three-year survival was
73% (Figure 1A). Median survival was approximately
five years.
In univariate analysis (Table 2), factors associated with
mortality were male sex, higher baseline mRAP on RHC,
higher baseline WHO FC, lower baseline 6MWD, peri-
cardial effusion, absence of warfarin therapy (Figure 1B)
and lack of combination therapy (Figure 1C).
Cox regression analysis was performed to make
adjustments for the effect of multiple covariates. In
regression analysis, we took into consideration a desired
ratio of independent-to-outcome variables of at most
one to five, in order to ensure model stability (Table 3)
[15]. Higher mRAP at diagnosis (HR = 1.13, 95% CI:
1.04 to 1.24, P = 0.007), lower baseline 6MWD (HR =
0.64, 95% CI: 0.43 to 0.97, P = 0.04), higher baseline
Table 1 Patient characteristics at baseline
Characteristic Mean + SD or n(%)
Total number of patients 117
Female 105 (89.7%)
Age at PAH diagnosis*, years 61.5 ± 11.4








Limited SSc 79 (72.5%)




Undifferentiated CTD 2 (1.8%)
Anti-centromere antibody positive 56 (47.9%)
Anti-Scl-70 antibody positive 9 (7.7%)
Anti-phospholipid antibodies 27 (23.1%)
WHO functional class
Class I 9 (7.7%)
Class II 14 (12.0%)
Class III 88 (75.2%)
Class IV 6 (5.1%)
Baseline 6MWD, m 325 ± 127
Baseline mRAP, mm Hg 6.9 ± 4.2
Baseline mPAP, mm Hg 35.9 ± 12.4
Baseline PCWP, mmHg 9.7 ± 3.9
Baseline CI, L/min/m2 2.6 ± 0.8
Baseline PVR, Wood units 6.9 ± 6.1
Pericardial effusion 14 (12.0%)
Warfarin therapy 36 (30.8%)
Pulmonary vasodilator therapy
Monotherapy 70 (59.8%)
Sequential monotherapy 12 (10.3%)
Combination therapy 34 (29.0%)
* date of PAH diagnosis is the date of right heart catheterisation
6MWD, six minute walk distance; CI, cardiac index; CTD, connective tissue
disease; MCTD, mixed connective tissue disease; mPAP, mean pulmonary
arterial pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial
hypertension; PVR, pulmonary vascular resistance; RA, rheumatoid arthritis; SD,
standard deviation; SLE, systemic lupus erythematosus; SSc, systemic sclerosis;
WHO, World Health Organization
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WHO FC (HR = 3.42, 95% CI: 1.25 to 9.36, P = 0.04)
and pericardial effusion (HR = 3.39, 95% CI: 1.07 to
10.68, P = 0.04) were predictive of mortality. Warfarin
(HR = 0.20, 95% CI: 0.05 to 0.78, P = 0.02) and combi-
nation pulmonary vasodilator therapy (HR = 0.20, 95%
CI: 0.05 to 0.83, P = 0.03) were protective. Male sex was
not independently associated with mortality and, there-
fore, was removed from the final model. Overall, survi-
val in patients with SSc (n = 104) was not significantly
different compared to those with other CTDs (n = 13)
(Figure 2). In further regression analyses of the SSc
patients only, treatment with warfarin (HR = 0.33, 95%
CI: 0.11 to 0.96, P = 0.04) and combination therapy
(HR = 0.55, 95% CI: 0.33 to 0.92, P = 0.02) remained
protective.
Warfarin therapy
Twenty-eight of 36 (77.8%) patients on warfarin had
SSc, 2 had MCTD, 2 SLE and 3 RA, and 1 had an undif-
ferentiated CTD. Ten of 36 patients on warfarin died
during follow-up. Among these, 7 had SSc, 1 had SLE, 1
MCTD and 1 RA. The main indication for anticoagula-
tion in all 36 patients was PAH. However, three patients
also had atrial fibrillation and three patients had a his-
tory of deep vein thrombosis (DVT). Of note, in the
three patients with the history of DVT, PAH was
deemed related to the CTD (WHO diagnostic group 1)
[16] and not pulmonary thromboembolic disease. The
target International Normalised Ratio (INR) in all
patients was 2.0 to 3.0.
Univariate comparisons of characteristics of patients




Figure 1 Survival from PAH diagnosis - (A) all patients and
grouped by (B) warfarin therapy and (C) combination PAH
therapy. PAH, pulmonary arterial hypertension.
Table 2 Predictors of mortality in CTD-PAH on univariate
analysis
Variable Unadjusted HR (95% CI) P
Male sex 3.42 (1.27 to 9.22) 0.02
Age at PAH diagnosis, years 1.01 (0.98 to 1.04) 0.72
Underlying CTD (SSc) 1.27 (0.44 to 3.66) 0.66
WHO FC at baseline 3.64 (1.32 to 10.01) 0.01
Baseline 6MWD* 0.70 (0.52 to 0.95) 0.02
Pericardial effusion 2.83 (1.12 to 7.12) 0.03
mPAP at baseline, mmHg 1.01 (0.98 to 1.05) 0.42
mRAP at baseline, mmHg 1.11 (1.02 to 1.19) 0.01
Warfarin therapy 0.26 (0.11 to 0.66) 0.004
Combination therapy 0.38 (0.16 to 0.92) 0.03
*hazard ratio relates to each 100 metres increase in 6MWD
6MWD, six minute walk distance; CTD, connective tissue disease; HR, hazard
ratio; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial
pressure; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis; WHO
FC, World Health Organization Functional Class
Table 3 Independent predictors of mortality in CTD-PAH,
determined using multivariable proportional hazards
regression analysis
Variable Adjusted HR (95% CI) P
WHO FC at baseline 3.42 (1.25 to 9.36) 0.04
mRAP at baseline, mmHg 1.13 (1.04 to 1.24) 0.007
Baseline 6MWD*, m 0.64 (0.43 to 0.97) 0.04
Pericardial effusion 3.39 (1.07 to 10.68) 0.04
Warfarin therapy 0.20 (0.05 to 0.78) 0.02
Combination therapy 0.20 (0.05 to 0.83) 0.03
*hazard ratio relates to each 100 metres increase in 6MWD
6MWD, six minute walk distance; 95% CI, 95% confidence interval; HR, hazard
ratio; mRAP, mean right atrial pressure; WHO FC, World Health Organization
functional class
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treated with warfarin are summarised in Table 4.
Patients on warfarin were significantly more likely to
have a pericardial effusion (42.0% vs 33.4%, P = 0.001)
and a higher baseline mPAP (42.0 vs 33.4 mm Hg, P =
0.001) than those not receiving warfarin. We found that
there was no significant difference in baseline mRAP or
baseline 6MWD between patients who were and those
who were not anticoagulated (Table 4).
Among patients who were not treated with warfarin, a
contraindication to anticoagulation was present in only
18 of 81 (22.2%) patients, and in the remainder the deci-
sion to not treat with warfarin was made at physician
discretion. The most common contraindication in 16
patients was a history of gastrointestinal bleeding, with
two other patients having a history of recurrent falls.
On follow-up, only one patient with SSc, who was on
warfarin for the treatment of PAH, had a complication
of GI bleeding.
Discussion
In this cohort study of patients with CTD-PAH con-
firmed by RHC, one- two- and three-year survivals were
94%, 89% and 73%, respectively. We found that indepen-
dent predictors of mortality were more severe PAH at
diagnosis, manifested by higher baseline mRAP, lower
baseline 6MWD, higher baseline WHO FC and the pre-
sence of pericardial effusion. After adjustment for these
covariates, anticoagulation and combination PAH ther-
apy increased survival.
Our one-year survival of 94% is higher than the one-
year survival of 86% reported by Chung et al. [5] in a
cohort of CTD-PAH patients from a multi-centre US-
based registry. Bearing in mind that the majority (95%)
of patients in our study had SSc, our survival rates are
also higher than those reported by Condliffe et al. [17]
from the UK pulmonary hypertension service, where
one-year survival was 78% and three-year survival was
47% in SSc-PAH, while one-year survival was 78% and
three-year survival was 74% in SLE-associated PAH.
There are several possible explanations for the differ-
ences in survival rates of our patients compared with
other cohorts. These include differences in hemody-
namic profile at PAH diagnosis and variations in the
approach to treatment, with a significant proportion of
p = 0.90 (Wilcoxon) 
Figure 2 Survival from PAH diagnosis of patients with SSc compared with those with other CTDs. PAH, pulmonary arterial hypertension;
SSc, systemic sclerosis; CTD, connective tissue disease.
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our patients receiving combination therapy. In addition,
it is possible that other cohorts may contain patients
with overall more severe CTD, who are more likely to
succumb to their disease.
Whilst elevated mRAP was associated with mortality in
our study, elevated mPAP was not significantly associated
with mortality in either univariate or multivariable analy-
sis. This apparent discrepancy between mPAP and mRAP
may be due to a proportion of patients having myocardial
disease due to SSc, thereby compromising the ability of
the right ventricle to generate an elevated mPAP. On the
other hand, mRAP better reflects right ventricular dys-
function and, therefore, continues to increase with wor-
sening disease. These relationships were borne out in a
systematic review of predictors of survival in IPAH which
found that whilst 10 publications evaluating this issue
supported the association between increased mPAP and
decreased survival, 19 did not [18]. In the same systema-
tic review, mRAP was the variable most commonly asso-
ciated with mortality, with an independent predictive
value for mortality reported in 17 of 28 studies.
6MWD is predictive of mortality in IPAH [19], and
has been used as a primary endpoint in clinical trials of
PAH therapy [20-24]. As 6MWD may be reduced due
to impaired mobility and joint or muscle pain, especially
in patients with CTD, some experts have considered it
to be a less useful measure of exercise capacity in those
with CTD-PAH than in those with IPAH [25]. Our find-
ings suggest that, despite these limitations in certain
individuals, 6MWD may still be a useful predictor of
mortality in CTD-PAH.
In our study, higher baseline WHO FC was also inde-
pendently predictive of mortality. The prognostic value
of WHO or New York Heart Association FC is supported
by multiple studies in PAH, several of which have
included patients with CTD-PAH [18]. Lack of improve-
ment in FC after specific PAH therapy has also been sug-
gested as an indication to escalate monotherapy to
combination therapy [2]. However, WHO FC is a subjec-
tive measure and does not always correlate with other
markers of PAH severity, such as mRAP and 6MWD
[26].
In IPAH, the presence of pericardial effusion has been
reported to be predictive of mortality in two retrospective
studies, and the severity of pericardial effusion has been
predictive of mortality in five retrospective studies [18]. In
our study, the presence of a pericardial effusion was pre-
dictive of mortality in CTD-PAH. This is consistent with
the findings of Fisher et al. [27]. Although the physiology
of the accumulation of fluid in the pericardial space is
incompletely understood, pericardial effusion in this con-
text is likely due to increased venous pressure and right
heart failure [28]. Importantly, in our patients, there were
no echocardiographic or other clinical features of serositis







Mean ± SD or n (%) Mean ± SD or n (%)
Female 34 (94.4%) 71(87.6%) 0.26
Age at CTD diagnosis, years 48.5 ± 14.3 51.1 ± 14.7 0.46
Age at PAH diagnosis*, years 59.7 ± 13.1 62.5 ± 10.6 0.23
Anti-phospholipid antibodies 8 (22.1%) 19 (23.5%) 0.74
Contraindication to anticoagulation 0 (0%) 18 (22.2%) 0.002
WHO functional class
Class I 0 (0%) 9 (11.1%)
Class II 3 (8.3%) 11 (13.6%) 0.09
Class III 32 (88.9%) 56 (69.1%)
Class IV 1 (2.8%) 5 (6.2%)
Baseline 6MWD, m 286.3 ± 116.4 339.5 ± 128.4 0.06
Baseline mRAP, mmHg 7.1 ± 4.3 6.9 ± 4.1 0.85
Baseline mPAP, mmHg 42.0 ± 11.5 33.4 ± 12.0 0.001
Pericardial effusion 9 (25.0%) 5 (6.2%) 0.004
Pulmonary vasodilator therapy
Monotherapy 13 (36.1%) 57 (71.3%)
Sequential monotherapy 2 (5.6%) 10 (12.5%) < 0.0001
Combination therapy 21 (58.3%) 13 (16.3%)
* date of PAH diagnosis is the date of right heart catheterisation
6MWD, six minute walk distance; CTD, connective tissue disease; ILD, interstitial lung disease; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial
pressure; PAH, pulmonary arterial hypertension; SD, standard deviation; SSc, systemic sclerosis; WHO, World Health Organization
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or pericarditis to indicate active inflammatory disease as
the cause for pericardial effusion.
In multiple regression analysis, after adjustment for
covariates, including use of specific PAH therapies, we
found that anticoagulation with warfarin conferred a
substantial survival benefit in CTD-PAH, which has not
previously been reported. Correlates of warfarin therapy
included more severe PAH, with anticoagulated patients
more likely to have a higher mPAP and a pericardial
effusion. This is consistent with an international survey
of PAH experts, which found that clinicians were more
likely to use warfarin in more severe CTD-PAH [29].
This survey also revealed variation in physician beliefs
and prescribing habits in relation to warfarin in CTD-
PAH. Whilst it is accepted that thrombotic arteriopathy
plays a role in the pathophysiology of PAH [30], the evi-
dence for a survival benefit with anticoagulation remains
limited. A survival benefit was suggested by a systematic
review of warfarin therapy in IPAH in which five of
seven retrospective analyses reported a survival benefit
with warfarin use [31]; no CTD-PAH patients were
included in this analysis. A recent observational study of
275 patients with SSc-PAH showed a low probability of
survival with warfarin; however, in this study, over a
third of the patients on warfarin were not receiving spe-
cific PAH therapies [32].
In our study, the most common documented contrain-
dication to anticoagulation in 16 patients was a history of
gastrointestinal bleeding. This is a major consideration in
patients with SSc-PAH as the prevalence of gastrointest-
inal vascular ectasia, a possible source of blood loss, is
reported to be as high as 5.7% [33].
It is possible that our finding of a survival benefit with
anticoagulation was confounded by sicker and frailer
patients with severe multi-organ CTD being less likely to
receive warfarin therapy. While data on PAH severity
and other SSc manifestations were collected, we did not
systematically collect data on non-SSc-related comorbid-
ities which may have impacted the patients’ overall health
status and suitability for anticoagulation. Despite our
efforts to adjust for all clinically important covariates, our
observational study cannot fully overcome the effect of all
potential confounders. Evaluation of the therapeutic effi-
cacy of anticoagulation in CTD-PAH warrants a more
definitive study, with random assignment of treatment in
patients with similar baseline characteristics.
Combination specific PAH therapy in CTD-PAH tar-
gets more than one of the multiple biologic pathways
involved in disease pathogenesis [2]. Although a number
of small, short-term trials of dual agent therapy have
been conducted, results have been disparate and there
are no data available beyond 12 weeks of therapy [2]. In a
cohort of 112 patients with PAH, among whom 40 had
CTD (29 had SSc), Keogh et al. recently reported survival
of 72% at 12 months and 48% at 24 months in patients
on dual specific PAH therapy [34].
In this study, we have sought to determine survival
and predictors of mortality in a cohort of CTD-PAH
patients sourced from multiple centres, typical of those
encountered in clinical practice. Although we included
all CTD-PAH patients at each site, there was potential
for selection bias in that the sites included in our study
were large academic centres. However, in practice, as
prescription of CTD-PAH therapy in Australia is limited
to large government designated centres, patients with all
grades of PAH severity are referred to these sites for
treatment.
Conclusions
Overall, the findings of this study suggest that treatment
with warfarin in addition to combination specific PAH
therapy may improve survival in CTD-PAH. The effi-
cacy of anticoagulation and combination therapy in
CTD-PAH merits further evaluation.
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